The fashion world’s biggest night in Milan turned contentious as critics decried the sponsorship of Vogue World 2026 by Eli Lilly, the pharmaceutical giant behind the popular weight-loss injections Mounjaro and the Foundayo pill. While supermodels Gigi Hadid and Jennifer Lopez captivated audiences on the runway, the involvement of a company whose products are increasingly being used for aesthetic weight loss has ignited fierce debate about body image, eating disorders and the fashion industry’s complex relationship with thinness.
A Controversial Partnership
The fifth edition of Anna Wintour’s Vogue World showcase, held at Milan’s iconic Leonardo da Vinci National Museum, was a spectacular affair featuring star-studded modelling and theatrical presentations. Yet tucked away in the event credits, Eli Lilly appeared as one of the so-called “fashion adjacent” sponsors, continuing a partnership that dates back to the 2025 Hollywood installment and the Met Gala livestream earlier this year.
While the collaboration doesn’t explicitly link Mounjaro or Foundayo to Vogue’s brand, the intersection of high fashion and pharmaceutical weight-loss solutions has drawn sharp criticism from eating disorder charities and academic experts who fear normalised medical interventions for body modification.
“The fashion industry has long promoted thinness through its imagery and casting practices,” explains Charlotte Markey, professor of psychology at Rutgers University and author of The Body Image book series. “Now, seeing a weight-loss drug manufacturer associated with such events suggests that thinness is being positioned as something we should aspire to—and potentially achieve through medical means.”
The Psychology of Body Image Under Scrutiny
Markey identifies the partnership as particularly troubling because it frames prescription medication as part of an aspirational lifestyle. “For audiences already exposed to intense appearance pressures, this normalises the idea that changing your body medically is simply another beauty or wellness choice,” she warns. “Publications like Vogue need to consider the broader psychological and cultural consequences of this messaging.”
Lauren Downing Peters, associate professor of fashion studies at Columbia College Chicago and author of Fashion Before Plus Size, observes that the sponsorship reflects how normalised GLP-1 medications have become in contemporary culture. “This isn’t just about fashion—it’s about how we define health, beauty and success in society,” Peters argues.
Eating disorder charity Beat has voiced serious concerns about the widespread use and promotion of GLP-1 drugs, particularly among vulnerable populations. “We’re particularly worried about these medications being attractive for those with eating disorders,” says Tom Quinn, Beat’s director of external affairs. “Given that the fashion industry has at times idealised unrealistic body ideals, partnering with Mounjaro’s manufacturer is a problematic association that could harm vulnerable individuals.”
Beyond the Runway: Industry Trends and Concerns
The criticism extends beyond the sponsorship itself to broader questions about representation in fashion. Recent data reveals a troubling trend: Vogue Business reported that in September 2025, 97.1% of looks in womenswear collections featured straight-size models (US 0-4, UK 4-8), while plus-size models (UK 18+) comprised just 0.9% of the runway. Only 2% featured mid-size models.
This shift has prompted questions about whether the return of ultra-thinness on catwalks reflects broader cultural pressures amplified by accessible weight-loss solutions. “The casting of plus-size models like Paloma Elsesser and Ashley Graham at Vogue World feels performative,” argues Felicity Hayward, a plus-size model advocating for genuine size inclusivity. “It reads as ‘size diversity cosplay’—checking boxes without addressing systemic issues.”
Hayward notably described the sponsorship choice as “advocating for thinness with a fog horn,” suggesting the messaging couldn’t be clearer about the event’s priorities.
Corporate Perspectives and Messaging
Eli Lilly frames its involvement through its 150th anniversary celebrations, emphasizing health over appearance. “This sponsorship is part of our 150 years of putting health above all,” states an Eli Lilly spokesperson. “We partner with cultural platforms like Vogue because that’s where conversations about bodies and health take place. Lilly is working to shift the conversation about weight from aesthetics to health and to challenge the stigma people with obesity face every day.”
The company’s involvement extends beyond simple branding, with a co-produced video titled “Portrait of Progress” comparing pharmaceutical innovation to fashion craftsmanship. The piece highlights Lilly’s century-long history of medical advancement while positioning health as the foundation for all creative achievement.
Why it Matters
This controversy illuminates the dangerous intersection of capitalism, body image and medicalisation in contemporary culture. When major fashion platforms legitimize pharmaceutical solutions to appearance-based pressures, they risk normalising potentially harmful shortcuts that could exacerbate mental health challenges for vulnerable individuals. The fashion industry’s historical promotion of unrealistic body standards meets today’s accessible medical tools, creating a perfect storm where eating disorders may find new avenues for validation. As society grapples with rising rates of body dissatisfaction and mental health struggles, events like Vogue World serve as crucial touchstones for examining whether our cultural institutions are perpetuating harmful norms or actively promoting healthier relationships with bodies and self-worth.
